What is ART-TG ?
The Technological Research Accelerator in Genomic Therapy (ART-TG) is a public R&D innovation center established by Inserm, the french national biomedical institution, to promote excellence in gene therapy research.
Advancing novel cell and gene therapy concepts towards clinical trials by bridging a gap between researchers/clinicians and industries, .
What do we provide ?
Dedicated scientific and pharmaceutical expertise for ex vivo ATMPs
Grant-funded scientific collaborations
Domains of interest:
Two fields in which gene therapy has high innovation potential:
immunotherapy (e.g. cancer, infectious diseases)
genetic disorders (especially sickle cell disease)
Within the Genopole campus, south of Paris, France.
Part of the "integrator" MAGENTA:
In 2020, the french government created the concept of "integrator" to recognize laboratories capable of addressing the challenges of industrial production of biomedicines.
The MAGENTA "integrator" was co-founded by ART-TG to foster innovation in cell and gene therapy by functioning at the public/private interface.
ART-TG seeks partners looking to innovate in the field of genomic therapy.
Inserm Transfert accompanies the partnerships of ART-TG.